Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting
Rhea-AI Summary
Axsome Therapeutics (NASDAQ: AXSM) is presenting new AUVELITY and solriamfetol data in major depressive disorder and obstructive sleep apnea at the ASCP 2026 Annual Meeting in Miami from May 26-29.
The company will share multiple poster presentations focused on anxious distress, anxiolytic effects, real-world outcomes, and neuropsychological measures.
Positive
- None.
Negative
- None.
News Market Reaction – AXSM
In the May 26 session, AXSM declined 0.75%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Awareness campaign | Neutral | -1.1% | Recognition of Mental Health Month and sharing mental-health resources. |
| May 05 | Investor conferences | Neutral | -0.3% | Participation in two May 2026 healthcare investor conferences. |
| May 04 | Earnings and update | Positive | +8.3% | Q1 2026 revenue growth led by AUVELITY and business update. |
| May 01 | FDA event | Positive | -0.6% | Investor event discussing AUVELITY FDA approval and commercial plans. |
| Apr 30 | FDA approval | Positive | +12.9% | FDA approval of AUVELITY for agitation in Alzheimer’s dementia. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive fundamental or regulatory news (earnings, FDA approval) has coincided with notable gains, while softer or awareness-focused news has seen modest or negative moves, including one divergence on an FDA-related investor event.
Over the last month, Axsome reported strong Q1 2026 results with net product revenue of $191.2M, followed by an 8.31% gain. FDA approval of AUVELITY for agitation in Alzheimer’s dementia on Apr 30 saw a 12.94% rise, while a related investor event on May 1 produced a small decline. More routine items like Mental Health Month recognition and conference participation had minimal impact. Today’s AUVELITY data presentations fit into this pattern of ongoing clinical and commercial expansion.
Key Terms
dextromethorphan-bupropion medical
major depressive disorder medical
anxious distress medical
real-world medical
neuropsychological outcomes medical
obstructive sleep apnea medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new AUVELITY® data in major depressive disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting being held from May 26-29 in Miami, FL.
Details of the presentations are as follows:
- Title: Effects of Dextromethorphan-Bupropion (45 mg/105 mg) in Participants with Major Depressive Disorder and Anxious Distress
Presentation Date and Time: Wednesday, May 27, 11:45 a.m. - 1:30 p.m. ET
Lead Author: Jeffrey R. Strawn, MD, Professor of Psychiatry and Behavioral Neuroscience, University of Cincinnati, OH
Poster Number: W42
- Title: Anxiolytic Effects of Dextromethorphan-Bupropion (45 mg/105 mg): Post Hoc Analyses Across Trials in Major Depressive Disorder
Presentation Date and Time: Wednesday, May 27, 11:45 a.m. - 1:30 p.m. ET
Lead Author: Jeffrey R. Strawn, MD, Professor of Psychiatry and Behavioral Neuroscience, University of Cincinnati, OH
Poster Number: W50
- Title: Real-World Clinical Outcomes of Patients Switching to Treatment with Dextromethorphan-Bupropion (45 mg/105 mg)
Presentation Date and Time: Thursday, May 28, 11:45 a.m. - 1:15 p.m. ET
Lead Author: Joel L. Young, MD, Medical Director of the Rochester Center for Behavioral Medicine, NY
Poster Number: T34
- Title: Effects of Solriamfetol on Neuropsychological Outcomes in Patients with Obstructive Sleep Apnea in the Real-World SURWEY Study
Presentation Date and Time: Thursday, May 28, 11:30 a.m. - 1:15 p.m. ET
Lead Author: Yaroslav Winter, MD, Mainz Comprehensive Epilepsy and Sleep Medicine Center, Department of Neurology, Johannes Gutenberg-University, Mainz, Germany
Poster Number: T29
About Axsome Therapeutics
Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investors:
Ashley Dong
Senior Director, Investor Relations
(929) 687-1614
adong@axsome.com
Media:
Darren Opland
Senior Director, Corporate Communications
(929) 837-1065
dopland@axsome.com
